Want help reviewing this study?
Study ID: NCT06951698. We help you review the study, but cannot decide medical eligibility.
RecruitingNCT06951698
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of manic episodes in Bipolarity type I
This study evaluates the safety and effectiveness of KarXT for people with bipolarity.
Medication studyAges 18–65Multiple countries
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of KarXT for people with bipolarity.
Who could participate?
This study is for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Bentonville, United States · Little Rock, United States and 69 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Registry last updated: · Record retrieved: . These dates do not confirm site availability.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 11, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 274
- Sponsor
- Bristol-Myers Squibb
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, New Zealand, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06951698
- Official title
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-1)
Recruitment & locations
RecruitingBentonville, United States · Little Rock, United States · Anaheim, United States
68 more locations
- Bellflower, United States
- Cerritos, United States
- Long Beach, United States
- Los Angeles, United States
- Montclair, United States
- New Haven, United States
- Hollywood, United States
- Homestead, United States
- Miami, United States
- Miami Lakes, United States
- West Palm Beach, United States
- Atlanta, United States
- Savannah, United States
- Chicago, United States
- Staten Island, United States
- North Canton, United States
- Austin, United States
- Irving, United States
- Richardson, United States
- ABB, Argentina
- Las Heras, Argentina
- Córdoba, Argentina
- Mendoza, Argentina
- Santiago del Estero, Argentina
- St Leonards, Australia
- Brisbane, Australia
- Kazanlak, Bulgaria
- Burgas, Bulgaria
- Haskovo, Bulgaria
- Novi Iskar, Bulgaria
- Pleven, Bulgaria
- Sliven, Bulgaria
- Vratsa, Bulgaria
- Győr, Hungary
- Budapest, Hungary
- Kōnan, Japan
- Toyoake, Japan
- Ichikawa, Japan
- Kitakyushu, Japan
- Obihiro, Japan
- Sapporo, Japan
- Moriguchi, Japan
- Karatsu-shi, Japan
- Iruma, Japan
- Kumagaya, Japan
- Kodaira, Japan
- tabashi City, Japan
- Fukuoka, Japan
- Miyazaki, Japan
- Osaka, Japan
- Tokyo, Japan
- Wakayama, Japan
- Yamagata, Japan
- Auckland, New Zealand
- Poznan, Poland
- Warsaw, Poland
- Bialystok, Poland
- Gdansk, Poland
- Rybnik, Poland
- Sosnowiec, Poland
- Tuszyn, Poland
- Dnipro, Ukraine
- Skarzhyntsi, Ukraine
- Kropyvnytskyi, Ukraine
- Kyiv, Ukraine
- Poltava, Ukraine
- Smila, Ukraine
- Ternopil, Ukraine
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of KarXT for people with bipolarity.
Who is behind this study?
The study sponsor is Bristol-Myers Squibb, a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including KarXT.
Who can participate?
This study is for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingACTRN12625000942459
A crossover study to investigate the safety, tolerability, pharmacokinetics, relative bioavailability, and pharmacodynamics of single doses of Katamine immediate release (KET-IR) and Ketamine abuse deterrent (KET-AD) oral ketamine capsules in healthy volunteers.
The registry lists this study as recruiting. Study locations are listed in Australia. Confirm recruitment at each site. It focuses on Bipolarity.
RecruitingNCT07286175
Brenipatide in adults with Bipolarity (RENEW-Bipolar-1)
The registry lists this study as recruiting. Study locations are listed in the United States, in Argentina, in Brazil, ... Confirm recruitment at each site. It is testing brenipatide for Bipolarity.
RecruitingNCT06696755
Adverse Events and Change for Bipolarity
The registry lists this study as recruiting. Study locations are listed in the United States. Confirm recruitment at each site. It is testing adverse Events and Change for Bipolarity.